Key facts
- It has raised $14.1M; the latest was Later Stage VC ($14.1M) in Dec 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, Qiming Venture Partners, GDD Industry Fund, Daoyuan Capital, Guangzhou Hi-tech Investment Group — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for PureVision
- ·The full record, as it builds
Funding rounds
No funding rounds for PureVision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PureVision
Developer of medical devices intended for targeted ophthalmic treatment. The company offers implantable stents, precision-engineered components, biocompatible materials, minimally invasive delivery systems, pressure-regulation mechanisms, and clinically validated designs, enabling glaucoma patients with therapeutic solutions.
- Sector
- Healthcare
- HQ
- Wenzhou, China
- Founded
- 2020
- Ownership
- Privately Held (backing)
PureVision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PureVision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PureVision in its N-PORT filings yet. We sweep new filings monthly.